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In the context of the joint project GANI_MED (Greifswald
Approach to Individualized Medicine) certain disease phe-
notypes and biomarker candidates are to be identified with
the help of association studies. Thus, GANI_MED aims at
contributing to the establishment of routines, improving
the implementation of PPPM in the clinical area. A unique
characteristic of GANI_MED is the integration of bioethics,
history of medicine and health economics throughout the
project. The volume starts with a definition of the term
“Individualized Medicine” (IM) which is resilient in terms
of academic science studies. This will be followed by a
chapter that focuses on the socio-cultural backgrounds of
IM from the perspective of history of medicine. It will
show that IM is also deeply rooted in broader societal
developments: the endeavor to extract more and more
socio-biological health information from populations in
order to detect risk factors and to get a valid data base for
conceptualizing efficient curative and preventive interven-
tions on an individual and population-based level. The
next chapter will provide deeper insights into medical-ana-
lytical research in the framework of GANI_MED: metabo-
lome-related biomarker research, non-pharmaceutical
interventions (the example of immunoadsorption) and
pharmacogenetics. Chapter 5 will deal with conceptual-
ethical questions and critiques of IM and wants to prove to
what extent these critiques are justifiable. It also deals with
the primary question of IM: do individual risks, that can be
detected, play a role for the demand for personal and joint
responsibility in a health care system which is shaped by
solidarity. A subchapter will deal with the question to what
extend IM will face social resistance if its promises of heal-
ing can only be formulated against the task of a good, free
and self-determined life in general. Beside conceptual ques-
tions, also application-orientated problems with regard to
research ethics of IM have been investigated within
GANI_MED. This includes the Informed Consent architec-
ture which was developed for the question, how partici-
pants can be included into such clinical-epidemiological
studies as well as considerations about the frequency and
processing of incidental findings. The concluding chapter
will focus on the questions related to the evaluation of
health economics: IM has the potential to alter the rules,
institutions and regulations of the health care sector.
However, there are major barriers preventing the key-
stakeholders to adopt this new approach to medicine.
Based on reliable methods of health economic evaluation
the relation between the effectiveness of some PPPM-
based therapies and the corresponding costs are calcu-
lated. This ratio can be regarded as a guiding criterion for
decision makers in the health care system for allocating
scare resources. The conclusion of the volume will be a
chapter in which the most important results from histori-
cal, ethical and health-economical single-case study will be
summed up.
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